

(Translation)

December 6, 2024

To Shareholders,

Company Name: Renaissance Inc.
Representative: Keisuke Furuta, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

**Notice regarding the occurrence of extraordinary profits and
revision of the full-year earnings forecast for the fiscal year ending March 2025**

We would like to announce that we have decided to revise our full-year earnings forecast for the fiscal year ending March 2025 (April 1, 2024 to March 31, 2025), which was announced on July 3, 2024, as follows.

Particulars

1. Revisions to the forecast of financial results for the current fiscal year (April 1, 2024 to March 31, 2025)

	Operating revenue	Operating profit	Ordinary income	Net income for the year	Net income for the year (Per share)
Previous forecast (A)	Millions of yen 105	Millions of yen △257	Millions of yen △257	Millions of yen △91	Yen Sen △7.18
Revised forecast (B)	127	△267	△267	46	3.67
Increase (Decrease) (B-A)	22	△10	△10	137	
Increase (Decrease) (%)	20.7	—	—	—	
(Reference) Results for the previous period (Fiscal year ended March, 2024)	194	△252	△251	△258	△20.32

2. Reason for revision

Operating revenue exceeded the initial forecast due to the acquisition of 21 million yen through the adoption of the "Smart Bio Drug Discovery Research Support Project" by the Japan Agency for Medical Research and Development (AMED). In addition, due to the termination of the CiCLE project ended in November 2024, we have revised our performance due to the recording of a 303 million yen debt forgiveness gain from the reduction of debt to the Japan Agency for Medical Research and Development (AMED) as extraordinary income.